PNC Financial Services Group Inc. cut its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 1.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,911 shares of the life sciences company’s stock after selling 274 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Integra LifeSciences Holdings Corporation were worth $1,303,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in IART. Strs Ohio grew its holdings in shares of Integra LifeSciences Holdings Corporation by 100.0% during the first quarter. Strs Ohio now owns 4,800 shares of the life sciences company’s stock valued at $202,000 after buying an additional 2,400 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in Integra LifeSciences Holdings Corporation by 100.0% during the first quarter. State Board of Administration of Florida Retirement System now owns 28,532 shares of the life sciences company’s stock valued at $1,202,000 after purchasing an additional 14,266 shares during the period. First Trust Advisors LP lifted its position in Integra LifeSciences Holdings Corporation by 106.7% during the first quarter. First Trust Advisors LP now owns 36,438 shares of the life sciences company’s stock valued at $1,535,000 after purchasing an additional 18,810 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Integra LifeSciences Holdings Corporation by 223.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 1,751 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its position in Integra LifeSciences Holdings Corporation by 76.0% during the first quarter. UBS Asset Management Americas Inc. now owns 39,907 shares of the life sciences company’s stock valued at $1,681,000 after purchasing an additional 17,229 shares during the period. 84.90% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Donald E. Morel, Jr. bought 2,500 shares of the stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $49.29 per share, with a total value of $123,225.00. Following the completion of the acquisition, the director now directly owns 29,612 shares in the company, valued at $1,459,575.48. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Barbara B. Hill bought 5,050 shares of the stock in a transaction dated Tuesday, August 1st. The stock was purchased at an average cost of $49.33 per share, for a total transaction of $249,116.50. Following the acquisition, the director now owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 17,550 shares of company stock worth $864,842. Insiders own 21.50% of the company’s stock.

A number of research analysts recently issued reports on IART shares. Oppenheimer Holdings, Inc. set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Saturday, June 24th. UBS AG restated a “buy” rating and set a $60.00 target price (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Friday, June 9th. Jefferies Group LLC restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Cantor Fitzgerald set a $65.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $57.00 target price for the company in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $54.45.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 51.51 on Friday. The firm has a market cap of $4.02 billion, a P/E ratio of 62.82 and a beta of 0.71. The firm has a 50 day moving average of $50.70 and a 200-day moving average of $49.16. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.45. The business had revenue of $282.16 million for the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The business’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.40 earnings per share. On average, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current year.

WARNING: “Integra LifeSciences Holdings Corporation (IART) Shares Sold by PNC Financial Services Group Inc.” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-shares-sold-by-pnc-financial-services-group-inc/1614599.html.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.